Research Article| Volume 19, ISSUE 2, P296-303, March 1997

The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules

  • Robert F. Kaiko
    Address correspondence to: Robert F. Kaiko, PhD, Medical Department, The Purdue Frederick Company, 100 Connecticut Avenue, Norwalk, CT 06850.
    Medical Department, The Purdue Frederick Company, Norwalk, Connecticut U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The effect of food intake on the pharmacokinetics of sustained-release (SR) morphine sulfate capsules was assessed in 24 healthy male volunteers. Subjects were randomized to receive a single, 20-mg SR morphine sulfate capsule while fasting and immediately after consumption of a standard high-fat meal. Plasma samples were masked for pharmacokinetic analysis. Although the extent of absorption of the SR preparation was comparable in subjects in the fed and fasted states, plasma morphine concentrations were significantly lower at most sampling times up to 10 hours when the drug was administered after a high-fat meal. The rate of absorption of morphine from the SR capsule was slower with food intake as evidenced by a 13% decrease in the maximum concentration (Cmax), a 28% increase in the half-life of absorption, and a 19% increase in the time to Cmax. Results of this study indicate that food intake had an effect on the overall plasma-concentration-versus-time profile of the SR morphine sulfate oral preparation, the extent of which was not revealed by a comparison of Cmax and area under the plasma concentration—time curve values alone.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • World Health Organization
        Cancer pain relief and palliative care.
        Technical Report Series 804. World Health Organization, Geneva1990
        • Jacox A
        • Carr DB
        • Pain R
        • et al.
        Management of cancer pain. Clinical Practice Guideline No. 9.
        AHCPR Publication No. 94-0592. US Department of Health and Human Services, Agency for Health Care Policy and Research, Rockville, Md1994
        • Kaiko RF
        • Lazarus H
        • Cronin C
        • et al.
        Controlled-release morphine bioavailability (MS Contin® Tablets) in the presence and absence of food.
        Hospice J. 1990; 6: 17-30
        • Kaiko RF
        • Grandy R
        • Thomas G
        • et al.
        A single-dose study of the effect of food ingestion and timing of dose administration on the pharmacokinetic profile of Roxanol SR 30 mg (sustained-release morhine sulfate) tablets.
        Curr Ther Res. 1990; 47: 869-878
        • Gourlay GK
        • Plummer JL
        • Cherry DA
        • et al.
        Influence of a high-fat meal on the absorption of morphine from oral solution.
        Clin Pharmacol Ther. 1989; 46: 463-468
        • US Food and Drug Administration
        Guidelines for oral extended (controlled) release dosage forms in vivo bioequivalence and in vitro dissolution testing. Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Md1993
        • Maccarrone C
        • West RJ
        • Broomhead AF
        • Hodsman GP
        Single dose pharmacokinetics of Kapanol, a new oral sustained-release morphine formulation.
        Drug Invest. 1994; 7: 262-274
        • Gourlay GK
        • Cherry DA
        • Onley MM
        • et al.
        Once a day (i.e. 24 hourly) Kapanol, a new sustained release morphine formulation, in the treatment of cancer pain: Pharmacokinetic aspects.
        Eur J Cancer. 1995; 31 (Abstract 897): S187
        • Gourlay GK
        • Plummer JL
        • Cherry DA
        • Onley MM
        A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: Pharmacokinetic aspects of morphine and morphine metabolites.
        in: Gebhart GF Hammond DL Jensen TS Proceedings of the 7th World Congress on Pain. Progress in Pain Management. 2. IASP Press, Seattle, Wash1994